RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study

Conditions

• Radiomic
• Radiomics
• Breast Cancer Metastatic
• Breast Cancer Stage IV
• Breast Carcinoma
• Breast Neoplasms
• Breast Cancer
• Breast Cancer With Bone Metastasis
• Breast Cancer With Metastatic Bone Disease
• Trastuzumab
• HER2
• HER2 + Breast Cancer
• HER2 Positive Breast Carcinoma
• HER2-positive Breast Cancer
• Her2/Neu Positive Advanced Solid Tumors
• HER2/Neu-positive Breast Cancer

Interventions

• DRUG: Trastuzumab deruxtecan (DS-8201a)

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano